Demographic Characteristics and Treatment Outcomes of Advanced Renal Cell Carcinoma With Clear Cell Histology: A Single-Center Experience From India

被引：0

作者：

Roy, Somnath ^{[1
]}

Biswas, Bivas ^{[1
]}

Dabkara, Deepak ^{[1
]}

Ganguly, Sandip ^{[1
]}

Ghosh, Joydeep ^{[1
]}

Bhattacharjee, Arnab ^{[1
]}

Ray, Kuntal ^{[1
]}

Mandal, Sayan ^{[1
]}

Patel, Yesha S. ^{[1
]}

Pal, Souhita ^{[1
]}

Karmakar, Jagriti ^{[1
]}

Mitra, Anindita ^{[1
]}

Bakshi, Rupsa ^{[1
]}

Mukhopadhyay, Sumit ^{[2
]}

Gupta, Sujoy ^{[3
]}

机构：

[1] Tata Med Ctr, Med Oncol, Kolkata, India

[2] Tata Med Ctr, Radiodiag, Kolkata, India

[3] Tata Med Ctr, Urol, Kolkata, India

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2024年 / 16卷 / 06期

关键词：

outcome; response; pazopanib; clear cell; renal cell carcinoma; CLINICAL-OUTCOMES; CANCER CENTER; SUNITINIB; SURVIVAL; PAZOPANIB; PATTERNS;

D O I：

10.7759/cureus.61978

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A total of 345 patients with metastatic clear cell histology were analyzed, with a median age of 61 years (range: 20-84 years). One hundred and eighty patients (52%) underwent nephrectomy before systemic therapy. The majority received pazopanib (257 patients, 75%), followed by sunitinib (36 patients, 10%) and cabozantinib (21 patients, 6%); 145 (45%) patients required dose interruption, and 143 (43%) required dose modification of TKI for adverse events. After a median follow-up of 44 months, the median progression-free survival (PFS) was 20.3 months (95% CI: 17.8-24.8), and the median overall survival (OS) was 22.7 months (95% CI: 18.8-28.3). In the poor-risk International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) group, no prior nephrectomy emerged as an independent poor-risk factor for both PFS and OS in multivariate analysis.

引用

页数：12

共 27 条

[1]

Bex A, 2019, JAMA ONCOL, V5, P164, DOI 10.1001/jamaoncol.2018.5543

[2] India's new health scheme: what does it mean for cancer care? [J].

Caduff, Carlo ;

Booth, Christopher M. ;

Pramesh, C. S. ;

Sullivan, Richard .

LANCET ONCOLOGY, 2019, 20 (06) :757-758

[3] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update [J].

Choueiri, Toni K. ;

Hessel, Colin ;

Halabi, Susan ;

Sanford, Ben ;

Michaelson, M. Dror ;

Hahn, Olwen ;

Walsh, Meghara ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

Feldman, Darren R. ;

Mangeshkar, Milan ;

Scheffold, Christian ;

George, Daniel ;

Morris, Michael J. .

EUROPEAN JOURNAL OF CANCER, 2018, 94 :115-125

[4] Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials [J].

Heng, D. Y. C. ;

Choueiri, T. K. ;

Rini, B. I. ;

Lee, J. ;

Yuasa, T. ;

Pal, S. K. ;

Srinivas, S. ;

Bjarnason, G. A. ;

Knox, J. J. ;

MacKenzie, M. ;

Vaishampayan, U. N. ;

Tan, M. H. ;

Rha, S. Y. ;

Donskov, F. ;

Agarwal, N. ;

Kollmannsberger, C. ;

North, S. ;

Wood, L. A. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :149-154

[5] External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Harshman, Lauren C. ;

Bjarnason, Georg A. ;

Vaishampayan, Ulka N. ;

Mackenzie, Mary ;

Wood, Lori ;

Donskov, Frede ;

Tan, Min-Han ;

Rha, Sun-Young ;

Agarwal, Neeraj ;

Kollmannsberger, Christian ;

Rini, Brian I. ;

Choueiri, Toni K. .

LANCET ONCOLOGY, 2013, 14 (02) :141-148

[6] Kidney cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India [J].

Joshi, Amit ;

Anand, Amitesh ;

Prabhash, Kumar ;

Noronha, Vanita ;

Shrirangwar, Sameer ;

Bakshi, Ganesh ;

Pal, Mahendra ;

Murthy, Vedang ;

Krishnatry, Rahul ;

Desai, Sangeeta ;

Menon, Santosh ;

Patil, Deepali ;

Kulkarni, Sheetal ;

Sable, Nilesh ;

Popat, Palak ;

Agrawal, Archi ;

Rangarajan, Venkatesh ;

Prakash, Gagan .

INDIAN JOURNAL OF CANCER, 2017, 54 (04) :601-604

[7] Sunitinib in metastatic renal cell carcimoma: A single-center experience [J].

Krishna, V. M. ;

Noronha, V ;

Prabhash, K. ;

Joshi, A. ;

Patil, V ;

Bhosale, B. ;

Ravi, T. ;

Menon, H. ;

Gupta, S. ;

Banavali, S. D. ;

Bakshi, G. ;

Tangaonkar, H. B. .

INDIAN JOURNAL OF CANCER, 2013, 50 (03) :268-273

[8] Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma [J].

Mejean, A. ;

Ravaud, A. ;

Thezenas, S. ;

Colas, S. ;

Beauval, J. -B. ;

Bensalah, K. ;

Geoffrois, L. ;

Thiery-Vuillemin, A. ;

Cormier, L. ;

Lang, H. ;

Guy, L. ;

Gravis, G. ;

Rolland, F. ;

Linassier, C. ;

Lechevallier, E. ;

Beisland, C. ;

Aitchison, M. ;

Oudard, S. ;

Patard, J. -J. ;

Theodore, C. ;

Chevreau, C. ;

Laguerre, B. ;

Hubert, J. ;

Gross-Goupil, M. ;

Bernhard, J. -C. ;

Albiges, L. ;

Timsit, M. -O. ;

Lebret, T. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05) :417-427

[9] INTERFERON ALFA-2A IN ADVANCED RENAL-CELL CARCINOMA - TREATMENT RESULTS AND SURVIVAL IN 159 PATIENTS WITH LONG-TERM FOLLOW-UP [J].

MINASIAN, LM ;

MOTZER, RJ ;

GLUCK, L ;

MAZUMDAR, M ;

VLAMIS, V ;

KROWN, SE .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1368-1375

[10] Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma [J].

Motzer, RJ ;

Mazumdar, M ;

Bacik, J ;

Berg, W ;

Amsterdam, A ;

Ferrara, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2530-2540

← 1 2 3 →